Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is...
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which...
Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara’s Cloudbreak platform for the development of...
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on...
Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Former...
Webcast presentation on Wednesday, February 14th at 10:30 AM ESTTHE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix...
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
MINNEAPOLIS, Feb. 09, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade...
IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)...
IRVING, Texas--(BUSINESS WIRE)--For the eighth consecutive year, McKesson has received approval from the Centers for Medicare & Medicaid Services (CMS)...
TORONTO, ON / ACCESSWIRE / February 8, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new...
—Company receives FDA IND clearance for the development of enobosarm in combination with GLP-1 drugs for potentially higher quality weight...
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse...
LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Cantargia (STO:CANTA) Cantargia AB will publish the company's year-end report for...
LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Cantargia (STO:CANTA) Cantargia AB will publish the company's year-end report for...
The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track...
LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®OCTOBER -...
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer...
Bria-Pros+ Activates Multiple Immune Cell Types Figure 1 shows that Bria-Pros+ activates a range of immune cells in a modified...